Nyxoah to Release Full Year 2021 Financial Results on March 24 and Host Conference Call on March 25, 2022

Nyxoah to Release Full Year 2021 Financial Results on March 24 and Host Conference Call on March 25, 2022

Mont–Saint–Guibert, Belgium "" March 3, 2022, 10:30pm CET / 4:30pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the full year 2021 on Thursday, March 24, 2022, after the market close. Company management will host a conference call to discuss financial results on Friday, March 25, 2022, beginning at 2:00pm CET / 8:00am ET.

Investors interested in listening to the conference call may do so by dialing (844) 260–3718 for those in the U.S., 0800 73264 for those in Belgium, or (929) 517–0938 for international callers, followed by Conference ID 3688760. A live and archived webcast of the event will be available on the Company's investor relations website at https://investors.nyxoah.com.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment


GLOBENEWSWIRE (Distribution ID 1000608577)

Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the 12 months ended December 31, 2021 on Tuesday, March 8, 2022 at 6:30 AM EST.

Entera's management will host a conference call later that morning, Tuesday, March 8, at 8:30 AM EST to discuss the results for the year. A question–and–answer session will follow Entera's remarks. To participate in the live call, please dial (877) 269–7756 (US) or (201) 689–7817 (international) or 1809406247 (Israel) and provide the conference ID "13727633" five to ten minutes before the start of the call.

To access a live audio webcast of the presentation on the "Investor Relations" page of Entera's website, please click here. A replay of the webcast will be archived on Entera's website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the phase 2 study for EB613. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Investors:

Nicole Jones
CG Capital
404–736–3838
entx@cg.capital


GLOBENEWSWIRE (Distribution ID 8496583)

Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the 12 months ended December 31, 2021 on Tuesday, March 8, 2022 at 6:30 AM EST.

Entera's management will host a conference call later that morning, Tuesday, March 8, at 8:30 AM EST to discuss the results for the year. A question–and–answer session will follow Entera's remarks. To participate in the live call, please dial (877) 269–7756 (US) or (201) 689–7817 (international) or 1809406247 (Israel) and provide the conference ID "13727633" five to ten minutes before the start of the call.

To access a live audio webcast of the presentation on the "Investor Relations" page of Entera's website, please click here. A replay of the webcast will be archived on Entera's website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the phase 2 study for EB613. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Investors:

Nicole Jones
CG Capital
404–736–3838
entx@cg.capital


GLOBENEWSWIRE (Distribution ID 8496583)

Dante Labs announces expansion of its Whole Genome Sequencing test with enhanced and broader offering

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, today announced the expansion of its Dante 30X Whole Genome Sequencing Test with personalized interpretation leveraging Dante's proprietary Extensa Software Platform.

The expanded offering includes sequencing in Dante's clinically validated and authorized labs. Notable improvements include:

  • enhanced reports with monthly updates for Dante's customers,
  • the most comprehensive suite of reports available for whole genome sequencing,
  • the most affordable 30X whole genome,
  • and one additional report delivered to customers per month – for free.

"This achievement is a milestone for Dante users and targets the growing need for comprehensive and affordable whole genome sequencing on a global scale," said Andrea Riposati, CEO of Dante Labs. "We are continually working to improve our offering as the field of genomics advances, and this is a tremendous step forward to bring best–in–class genomics to more people at affordable prices."

Whole Genome Sequencing is superior to traditional small panels in that it is the broadest and most comprehensive DNA analysis. This more personalized approach delivers clinical answers to prevent, track and treat diseases without missing certain variants missed by more targeted approaches.

Dante's Extensa software platform is a proprietary, scalable solution to interpret and transform genomic information into clinically actionable results.

About Dante Labs

Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:

Laura D'Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantelabs.com


GLOBENEWSWIRE (Distribution ID 8496284)

Zoho Takes on Current Low-Code Market Gaps with New Creator Platform to Empower Businesses to Easily Build, Deploy, Manage, and Analyze Custom Solutions

Austin, Texas, March 03, 2022 (GLOBE NEWSWIRE) — Today, Zoho Corporation, a leading global technology company, announced the latest version of its low–code offering, Zoho Creator Platform, an all–in–one solution that bridges the gap between business users and IT teams by providing a low–code solution–building experience regardless of technical know–how. Organizations currently face soaring demand for new business software, but existing low–code platforms for business users only facilitate basic app building, lacking the sophistication needed to develop scalable, enterprise–ready end–to–end tools. Existing solutions in the market designed specifically for business users facilitate only basic app building, lacking the complexity needed to develop end–to–end tools, which allow organizations to scale and ensure centralized governance.

Addressing the needs of both business users and IT teams, Zoho Creator Platform supports all levels to build, manage, integrate, and analyze for a complete low–code experience, enabling 10X faster deployment than any other solution on the market. Democratizing access to low–code development tools allows IT and business users to work in tandem to create and deploy apps that are highly customized, while minimizing common interoperability, permissions, and governance challenges.

“Currently there isn't a low–code solution on the market that allows both business users and IT to truly build end–to–end business solutions,” said Raju Vegesna, Chief Evangelist, Zoho Corporation. “With this update, Zoho's Creator Platform combines application development, integrations, process automation, business intelligence and analytics into a single platform while simultaneously enabling IT teams to effortlessly manage security, compliance, and governance challenges. Organizations can now leverage a unified solution for all of their low–code needs, extending the ability to innovate to every employee.”

The Zoho Creator Platform integrates digital data and processes to facilitate the creation of truly agile solutions for business users and IT teams alike. Business developers can now easily build scalable low–code solutions which include apps, integrations, analytics, and process automation without heavy dependency on IT teams or time–consuming training. For IT stakeholders, the Platform now provides deeper controls around governance and management, without compromising automation, data–driven insights, customization, and the ability to affect revenue and growth. Together, business users and IT can quickly deploy secure, dynamic solutions built to auto–scale, so that organizations can focus on solving business problems and pursue new opportunities.

"We needed a complete solution to resolve specific operational difficulties, including a lack of streamlined communication and an inability to oversee employees effectively. The Zoho Creator Platform allowed us to build new contextual tools that unify disjointed communication channels, automate processes, and seamlessly integrate into our existing system,” said Gaurav Kakkar, System Process Manager at Emirates Logistics. “Additionally, the new Platform has given specific administrators greater flexibility in implementing new processes through the sandbox and demo user options to keep our data secure while providing important business insights. Together, we're able to better support employees to be more productive, enabling them to collaborate and spot opportunities to better serve themselves and customers."

"With this version of Creator, Zoho is shifting its low–code emphasis from applications to business solutions,” said Jason Bloomberg, President of Intellyx, an industry research firm. “Creator helps business stakeholders and IT personnel collaborate to combine applications, business intelligence and analytics, and process automation into end–to–end business solutions. Creator is simple enough for nontechnical staff while also powerful enough to address complex workflow scenarios in a secure, scalable environment.”

Key areas of innovation in the new Creator Platform include:

Expand App Building to Solution Building

Unified Solution Builder – Create, integrate, analyze, and manage custom business solutions at scale from a single dashboard. Seamlessly switch between different elements, with deep interoperability between capabilities, and in–built guardrails for IT teams to drive enterprise–wide citizen development programs.

Artificial Intelligence (AI) – Zoho's intelligent AI assistant (Zia) now enables developers to import data from anywhere, cleanse and transform with one click, build data models, and automatically detect data relationships via Smart Import. AI tasks such as predictive analytics, keyword extraction, sentiment analysis, OCR, and object detection are built into the drag–and–drop user interface for easy deployment.

Process Blueprinting – This intuitive drag–and–drop builder graphically constructs an online replica of a business process by specifying each step, assigning responsibilities across stakeholders, and automating actions based on pre–set conditions. Users can now identify bottlenecks and have clarity to facilitate scalability for evolving business needs.

Enhanced Serverless Functions – Developers can now write, store, and execute reusable code blocks in Zoho Creator Platform using Deluge, Java, or Node.js. These functions encourage IT and business teams to work together to build scalable and easily maintainable enterprise–ready apps faster.

Build a Connected Ecosystem of Solutions for a Seamless Experience

Unified Data Modeling (UDM) – Unchecked data points, varied data formats, and evolving app landscapes add layers of difficult–to–solve complexities to data integration, resulting in sub–optimal business results. Universal cloud modeling is now included to help developers establish secure data transfer by automating data integration protocols with unified data architecture and over 600 plug–and–play connectors to make data integration easier for users.

Integration Status Dashboard – Users have complete visibility on how well each integration operates with the new Integration Status Dashboard. Status Dashboard provides key findings on recent executions, success and failure stats, and top connections facilitating early error detection and resolution to enable organizations to discover errors and resolve them quicker.

Embedded BI and Analytics Engine – An industry–first, full–fledged business intelligence and analytics engine is now included in the Zoho Creator Platform, enabling users to derive business insights from the data residing in their applications without worrying about bringing another subscription into the fold. High–end BI functionalities like predictive analytics, data alerts, what–if analysis, data blending, and conversational analytics are all now supported on the low–code platform.

Increased Control for IT with End–to–End ADLM

Environments – Developers can now launch solutions in different environments of choice""development, staging (testing), or production""with a single click based on the readiness of the solution. This allows users to add features continuously or make changes without disturbing the existing app in production. The environments also support role–based access to help business developers simulate user–specific experience validation.

Centralized Governance – To help IT manage low–code development, features such as granular role–based access controls, comprehensive audit trails and backup options, application IDE, dashboards to view and manage users, billing dashboard, personalization options such as localization, branding customization, and more, are now available in the low–code platform.

Integrated Communication and Collaboration Aid – Often, business developers get stuck in the build phase with minor obstacles, especially when new to the platform. In order to enhance communication and collaboration, integrated communication enables messaging, sending files, sharing screens, and the ability to make audio and video calls.

Zoho Creator Platform Pricing

Pricing starts at $25 USD per employee, with a 15–day trial available. For comprehensive pricing information, please visit: https://www.zoho.com/creator/pricing.html

Zoho Privacy Pledge

Zoho respects user privacy and does not have an ad–revenue model in any part of its business, including its free products. More than 75 million users around the world, across hundreds of thousands of companies, rely on Zoho every day to run their businesses, including Zoho itself. For more information, please visit: https://www.zoho.com/privacy–commitment.html

About Zoho

With 50+ apps in nearly every major business category, including sales, marketing, customer support, accounting and back–office operations, and an array of productivity and collaboration tools, Zoho Corporation is one of the world's most prolific technology companies.

Zoho is privately held and profitable with more than 10,000 employees. Zoho is headquartered in Austin, Texas, with international headquarters in Chennai, India. Additional offices are in the United States, India, Japan, China, Canada, Singapore, Mexico, Australia, the Netherlands, Brazil, Saudi Arabia, and the United Arab Emirates. For more information, please visit: www.zoho.com/

Attachments


GLOBENEWSWIRE (Distribution ID 8495995)